Dexcom, Inc.'s (NASDAQ:DXCM) fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus ...
Looking forward, DexCom's management has reiterated its fiscal year 2025 forecast, anticipating revenue growth of 14% with a ...
Hosted on MSN23h
Dexcom Stock Makes A Recovery After Its Fourth-Quarter FumbleDexcom stock stock recovered Friday after the diabetes devices maker missed fourth-quarter profit expectations.
Medical device maker Dexcom beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with diabetes.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an ...
Medical device company DexCom (NASDAQ:DXCM) reported Q4 CY2024 results topping the market’s revenue expectations, with sales ...
DexCom (NASDAQ: DXCM) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track ...
Today, Benzinga's options scanner identified 8 options transactions for DexCom. This is an unusual occurrence. The sentiment ...
Continuous glucose monitors like Dexcom's Stelo and Abbott's Lingo are small, wearable devices that track blood glucose levels in real-time in non-diabetics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback